Flagship Harbor Advisors LLC purchased a new stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 788 shares of the biopharmaceutical company’s stock, valued at approximately $109,000.

Other large investors have also recently modified their holdings of the company. WealthTrust Fairport LLC purchased a new position in GW Pharmaceuticals PLC- during the first quarter valued at approximately $104,000. Stratos Wealth Partners LTD. lifted its holdings in GW Pharmaceuticals PLC- by 216.0% during the first quarter. Stratos Wealth Partners LTD. now owns 948 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 648 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in GW Pharmaceuticals PLC- during the second quarter valued at approximately $119,000. Cowen Prime Services LLC lifted its holdings in GW Pharmaceuticals PLC- by 708.0% during the second quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 885 shares in the last quarter. Finally, NumerixS Investment Technologies Inc purchased a new position in GW Pharmaceuticals PLC- during the second quarter valued at approximately $166,000. 75.44% of the stock is currently owned by institutional investors and hedge funds.

GWPH stock opened at $140.94 on Tuesday. GW Pharmaceuticals PLC- has a one year low of $96.42 and a one year high of $164.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.21 and a current ratio of 8.67.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. The firm had revenue of $3.46 million for the quarter, compared to the consensus estimate of $2.00 million. equities research analysts anticipate that GW Pharmaceuticals PLC- will post -9.11 earnings per share for the current fiscal year.

Several brokerages have weighed in on GWPH. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Thursday, August 2nd. Cantor Fitzgerald set a $235.00 price target on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Thursday, July 12th. BidaskClub downgraded shares of GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating in a report on Friday, June 8th. Stifel Nicolaus began coverage on shares of GW Pharmaceuticals PLC- in a report on Tuesday, August 14th. They set a “buy” rating and a $181.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Friday, August 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $181.38.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: Google Finance Portfolio Tips and Tricks

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.